Gilead Sciences to buy 49.9% stake in Pionyr Immunotherapeutics for $275m

This article was originally published here

The deal also provides Gilead with an exclusive option to acquire the remaining stake in Pionyr for around $315m. The shareholders of Pionyr will secure up to an

The post Gilead Sciences to buy 49.9% stake in Pionyr Immunotherapeutics for $275m appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply